RxDoctor Payments Data

Brent Berry

Neurology · Golden Valley, MNNPI 1013263011

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $113,235 of the $140,537 with a category attached, or 80.6%. Eisai Inc. accounts for 70.6% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $121,683, more than ten times the $216 reported in 2023. Among neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$140,537in general payments, 2019–2025

Across 218 payments — averaging $644.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$99K
  • Lilly USA, LLC$41K
  • W. L. Gore & Associates, Inc.$128
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • Teva Pharmaceuticals USA, Inc.$45
  • UCB, Inc.$33
  • plus $249 from 13 others

What the payments were for

  • Consulting fees$4,6903%
  • Speaking & faculty fees$113,23581%
  • Travel & lodging$19,33214%
  • Food & beverage$3,2802%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$140,537 in reported general payments places this provider in the 95th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$155,892
Medicare patients
270
Services billed
41,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam65$2,534
Carbidopa-LevodopaCarbidopa/Levodopa90$2,121
Lamotrigine25$1,026
Gabapentin28$894
Donepezil Hcl39$625
Levetiracetam ErLevetiracetam14$567
Pregabalin12$240
Topiramate14$212
Sumatriptan Succinate11$150
Tizanidine Hcl15$114
Risperidone12$52
Lorazepam14$20

Paid to pharmacies, not to this prescriber.

Other neurology in Golden Valley

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →